- Home
- ASPN vs FULC Comparison
ASPN vs FULC Comparison
Compare ASPN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPN
- FULC
- Stock Information
- Founded
- ASPN 2001
- FULC 2015
- Country
- ASPN United States
- FULC United States
- Employees
- ASPN N/A
- FULC N/A
- Industry
- ASPN RETAIL: Building Materials
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- ASPN Consumer Discretionary
- FULC Health Care
- Exchange
- ASPN Nasdaq
- FULC Nasdaq
- Market Cap
- ASPN 573.2M
- FULC 469.0M
- IPO Year
- ASPN 2014
- FULC 2019
- Fundamental
- Price
- ASPN $7.74
- FULC $9.02
- Analyst Decision
- ASPN Buy
- FULC Buy
- Analyst Count
- ASPN 6
- FULC 7
- Target Price
- ASPN $14.40
- FULC $10.43
- AVG Volume (30 Days)
- ASPN 2.0M
- FULC 578.7K
- Earning Date
- ASPN 11-06-2025
- FULC 10-29-2025
- Dividend Yield
- ASPN N/A
- FULC N/A
- EPS Growth
- ASPN N/A
- FULC N/A
- EPS
- ASPN N/A
- FULC N/A
- Revenue
- ASPN $397,175,000.00
- FULC N/A
- Revenue This Year
- ASPN N/A
- FULC N/A
- Revenue Next Year
- ASPN $8.56
- FULC N/A
- P/E Ratio
- ASPN N/A
- FULC N/A
- Revenue Growth
- ASPN 11.18
- FULC 2752.05
- 52 Week Low
- ASPN $4.16
- FULC $2.32
- 52 Week High
- ASPN $18.95
- FULC $10.11
- Technical
- Relative Strength Index (RSI)
- ASPN 48.75
- FULC 51.00
- Support Level
- ASPN $7.52
- FULC $8.42
- Resistance Level
- ASPN $8.56
- FULC $10.09
- Average True Range (ATR)
- ASPN 0.48
- FULC 0.82
- MACD
- ASPN -0.08
- FULC -0.12
- Stochastic Oscillator
- ASPN 12.04
- FULC 40.56
About ASPN Aspen Aerogels Inc.
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.